We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Touts Bayesian Methods for Phase II Trials, More Cautious on Phase III
FDA Touts Bayesian Methods for Phase II Trials, More Cautious on Phase III
While the FDA sees great potential for Bayesian statistics in Phase II clinical trials, the agency is not yet ready to endorse the method for Phase III studies.